Press Releases
Packaging & Labelling
Singapore Airlines Cargo Broadens Range Of Solutions For Pharmaceutical Cargo
Patients at Medison’s network of clinics will gain access to next generation treatments and therapies by being matched to leading-edge, international clinical trials. This will also accelerate the launch of new treatments and medications in Georgia.
The Medison network of...
Packaging & Labelling
Pharmaceutical packaging: Advantages of digital printing technology in blister packaging
Producing pharmaceutical products for the global market is hugely challenging and complex.
When a drug is set to be sold in multiple countries, it needs to be packaged in a way which accommodates the regulatory requirements and specific artwork demands...
Drug Research
Pathogen engineered to self destruct underlies cancer vaccine platform
A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-destruct once they've done their job, making it safe for use in humans. The...
Drug Research
Artificial DNA can control release of active ingredients from drugs
A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was once a pharmacologist's dream is now much closer to...
Clinical Trials
SpringWorks and GSK sign clinical trial collaboration agreement
SpringWorks Therapeutics has signed an agreement to assess its nirogacestat in combination with GlaxoSmithKline’s (GSK) belantamab mafodotin to treat patients with relapsed or refractory multiple myeloma.
Under the clinical trial collaboration agreement, GSK will sponsor and conduct an adaptive Phase...
Press Releases
Velabs Therapeutics Announces 3 Million Series B Financing to Advance its Functional Antibody Screening Programme
Velabs Therapeutics GmbH, a leader in rapid screening of functional therapeutic antibodies, announced the closing of a €3 million Series B financing round to advance its functional antibody screening programme and to strengthen its own pipeline of preclinical functional...
Press Releases
AbbVie Announces US FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax in Patients with Multiple Myeloma Positive for the Genetic Abnormality
AbbVie , a research-based global biopharmaceutical company announced that the U.S. FDA has lifted the partial clinical hold placed on CANOVA (M13-494), a Phase 3 trial evaluating venetoclax (VENCLEXTA® OR VENCLYXTO®) for the investigational treatment of relapsed/refractory multiple myeloma....
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read